Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

To scan or not to scan: DaT is the question.

Perlmutter JS, Eidelberg D.

Neurology. 2012 Mar 6;78(10):688-9. doi: 10.1212/WNL.0b013e3182494c72. Epub 2012 Feb 8. No abstract available.

PMID:
22323757
2.

Role of DAT-SPECT in the diagnostic work up of parkinsonism.

Scherfler C, Schwarz J, Antonini A, Grosset D, Valldeoriola F, Marek K, Oertel W, Tolosa E, Lees AJ, Poewe W.

Mov Disord. 2007 Jul 15;22(9):1229-38. Review.

PMID:
17486648
3.

PET and SPECT in common neuropsychiatric disease.

Tatsch K, Ell PJ.

Clin Med (Lond). 2006 May-Jun;6(3):259-62. Review. No abstract available.

PMID:
16826858
4.

[Neuroimaging present and future].

Fukuyama H.

No To Shinkei. 2005 May;57(5):387-96. Review. Japanese. No abstract available.

PMID:
15981638
5.
6.

Functional imaging in Parkinson's disease.

Dagher A.

Semin Neurol. 2001;21(1):23-32. Review.

PMID:
11346022
7.

Functional brain imaging in late-life depression and dementia.

Kumar A.

J Clin Psychiatry. 1993 Nov;54 Suppl:21-5. Review.

PMID:
8270594
8.
9.

Role of dopamine transporter imaging in routine clinical practice.

Marshall V, Grosset D.

Mov Disord. 2003 Dec;18(12):1415-23. Review.

PMID:
14673877
10.

Altropane. O 587.

[No authors listed]

Drugs R D. 2002;3(3):188-9. Review. No abstract available.

PMID:
12099164
11.

SPECT imaging of the dopaminergic system in (premotor) Parkinson's disease.

Booij J, Knol RJ.

Parkinsonism Relat Disord. 2007;13 Suppl 3:S425-8. doi: 10.1016/S1353-8020(08)70042-7. Review.

PMID:
18267276
12.

[Nuclear medicine imaging in neurodegenerative dementias].

Gratz S, Hahn U, Kaiser JW, Jarnig M, Schwarz J, Förstl H.

Dtsch Med Wochenschr. 2008 May;133 Suppl 1:S5-7. doi: 10.1055/s-2008-1075678. Review. German.

PMID:
18437639
13.

DAT imaging in drug-induced and psychogenic parkinsonism.

Tolosa E, Coelho M, Gallardo M.

Mov Disord. 2003 Oct;18 Suppl 7:S28-33. Review.

PMID:
14531043
14.

Diagnosis and initiation of treatment in Parkinson's disease.

Lyons KE, Pahwa R.

Int J Neurosci. 2011;121 Suppl 2:27-36. doi: 10.3109/00207454.2011.620197. Review.

PMID:
22035027
15.

Functional imaging of non-motor signs in Parkinson's disease.

Ballanger B, Poisson A, Broussolle E, Thobois S.

J Neurol Sci. 2012 Apr 15;315(1-2):9-14. doi: 10.1016/j.jns.2011.11.008. Epub 2011 Dec 9. Review.

PMID:
22154188
16.

A perspective on the current issues in the diagnosis of Parkinson's disease.

Worth PF.

Br J Hosp Med (Lond). 2007 May;68(5):S6, S8-11, S14-5. Review.

PMID:
17554947
17.

Neuroimaging and transcranial ultrasonography in Parkinson's disease.

Mehta SH, Morgan JC, Sethi KD.

Curr Neurol Neurosci Rep. 2008 Jul;8(4):297-303. Review.

PMID:
18590613
18.

The role of DAT-SPECT in movement disorders.

Kägi G, Bhatia KP, Tolosa E.

J Neurol Neurosurg Psychiatry. 2010 Jan;81(1):5-12. doi: 10.1136/jnnp.2008.157370. Review.

PMID:
20019219
19.

Relationship between SLC6A3 genotype and striatal dopamine transporter availability: a meta-analysis of human single photon emission computed tomography studies.

Costa A, Riedel M, Müller U, Möller HJ, Ettinger U.

Synapse. 2011 Oct;65(10):998-1005. doi: 10.1002/syn.20927. Epub 2011 Mar 28. Review.

PMID:
21404331
20.

Molecular neuroimaging: from conventional to emerging techniques.

Hammoud DA, Hoffman JM, Pomper MG.

Radiology. 2007 Oct;245(1):21-42. Review.

PMID:
17885179

Supplemental Content

Support Center